{"nctId":"NCT00878709","briefTitle":"Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer","startDateStruct":{"date":"2009-07-09","type":"ACTUAL"},"conditions":["Breast Cancer"],"count":2840,"armGroups":[{"label":"Neratinib","type":"EXPERIMENTAL","interventionNames":["Drug: neratinib"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: placebo"]}],"interventions":[{"name":"neratinib","otherNames":["HKI-272","Nerlynx"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Stage II through IIIC HER-2/erbB-2 positive breast cancer with node positive disease.\n* Been treated for early breast cancer with standard of care duration of trastuzumab.\n* Could have been treated neoadjuvantly but have not reached pathologic complete response.\n\nExclusion Criteria:\n\n* Positive clinical and radiologic assessments for local or regional recurrence of disease at the time of study entry.\n* History of heart disease.\n* Corrected QT (QTc) interval \\>0.45 seconds\n* History of gastrointestinal disease with diarrhea as the major symptom.","healthyVolunteers":false,"sex":"FEMALE","genderBased":true,"minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2","description":"Invasive disease-free survival time is defined as the time from date of randomization until the first disease recurrence of the following events: invasive ipsilateral breast tumor recurrence, invasive contralateral breast cancer, local/regional invasive recurrence, distant recurrence and death from any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"7.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Kaplan-Meier Estimates of Invasive Disease-free Survival (iDFS) at Year 2 by Treatment Arms","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.2","spread":null},{"groupId":"OG001","value":"91.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was defined as the time from randomization to death due to any cause, censored at the last date known alive.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.64","spread":null},{"groupId":"OG001","value":"99.43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.74","spread":null},{"groupId":"OG001","value":"96.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.09","spread":null},{"groupId":"OG001","value":"93.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.36","spread":null},{"groupId":"OG001","value":"91.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.06","spread":null},{"groupId":"OG001","value":"88.65","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-free Survival Including Ductal Carcinoma in Situ (DFS-DCIS) in Neratinib Arm Compared to Placebo Arm at Year 2","description":"Disease-free survival including DCIS time is defined as the time from date of randomization until the first occurrence of DCIS or an iDFS event (an iDFS event including invasive ipsilateral breast tumor recurrence, invasive contralateral breast cancer, local/regional invasive recurrence, or distant recurrence and death from any.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"8.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimates of Disease-free Survival Including Ductal Carcinoma in Situ (DFS-DCIS) at Year 2 by Treatment Arms","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.2","spread":null},{"groupId":"OG001","value":"91.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Distant Disease-free Survival (DDFS) in Neratinib Arm Compared to Placebo Arm at Year 2","description":"Distant disease-free survival time is defined as the time from date of randomization until the first occurrence of distant recurrence or death from any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null},{"groupId":"OG001","value":"5.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimates of Distant Disease-free Survival (DDFS) at Year 2 by Treatment Arms","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"94.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Time to Distant Recurrence (TTDR) Event in Neratinib Arm Compared to Placebo Arm at Year 2","description":"Percentage of Participants with TTDR events is reported. TTDR is defined as the time from date of randomization until the first occurrence of distant recurrence or death from breast cancer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimates of Time to Distant Recurrence (TTDR) Survival at Year 2 by Treatment Arms","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.5","spread":null},{"groupId":"OG001","value":"94.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Central Nervous System Recurrence in Neratinib Arm Compared to Placebo Arm at Year 2","description":"CNS recurrence is defined as the time from randomization to CNS as the first distant recurrence. Competing events include distant recurrence at other sites as the first distant recurrence and death from any cause prior to distant recurrence.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of Central Nervous System Recurrence (CNS) at Year 2","description":"Cumulative incidence of Central Nervous System Recurrence (CNS) is estimated by Gray's method (Gray,1988).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":null},{"groupId":"OG001","value":"1.16","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 5","description":"Invasive disease-free survival time is defined as the time from date of randomization until the first disease recurrence of the following events: invasive ipsilateral breast tumor recurrence, invasive contralateral breast cancer, local/regional invasive recurrence, distant recurrence and death from any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null},{"groupId":"OG001","value":"11.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Kaplan-Meier Estimates of Invasive Disease-free Survival (iDFS) at Year 5 by Treatment Arms","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.2","spread":null},{"groupId":"OG001","value":"87.7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Disease-free Survival Including Ductal Carcinoma in Situ (DFS-DCIS) in Neratinib Arm Compared to Placebo Arm at Year 5","description":"Disease-free survival including DCIS time is defined as the time from date of randomization until the first occurrence of DCIS or an iDFS event (an iDFS event including invasive ipsilateral breast tumor recurrence, invasive contralateral breast cancer, local/regional invasive recurrence, or distant recurrence and death from any.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":null},{"groupId":"OG001","value":"12.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Distant Disease-free Survival (DDFS) in Neratinib Arm Compared to Placebo Arm at Year 5","description":"Distant disease-free survival time is defined as the time from date of randomization until the first occurrence of distant recurrence or death from any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null},{"groupId":"OG001","value":"9.2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Time to Distant Recurrence (TTDR) Event in Neratinib Arm Compared to Placebo Arm at Year 5","description":"Percentage of Participants with TTDR events is reported. TTDR is defined as the time from date of randomization until the first occurrence of distant recurrence or death from breast cancer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null},{"groupId":"OG001","value":"8.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cumulative Incidence of Central Nervous System Recurrence (CNS) at Year 5","description":"Cumulative incidence of Central Nervous System Recurrence (CNS) is estimated by Gray's method (Gray,1988).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"1.82","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":103,"n":1408},"commonTop":["Diarrhoea","Nausea","Fatigue","Headache","Abdominal pain"]}}}